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Zusammenfassung
Eine deutsche Arbeitsgruppe aus 23 Brustkrebsexperten hat die 
Abstimmungsergebnisse der diesjährigen St.-Gallen-Konsen-
suskonferenz zur primären Behandlung des Mammakarzinoms 
(11.–14. März 2009) kommentiert und für den Therapiealltag in 
Deutschland konkretisiert. Vor dem Hintergrund, dass das Kon-
zept der St.-Gallen-Konsensuskonferenz nur einen Minimalkon-
sensus erlaubt, war es das Ziel der Arbeitsgruppe, praxisrele-
vante Empfehlungen für den klinischen Alltag in Deutschland 
zu geben. Ein inhaltlicher Schwerpunkt war in St. Gallen die 
Tumorbiologie als Ausgangspunkt für die individuelle Thera-
pieentscheidung. Intensiver Diskussionsbedarf bestand bei der 
klinischen Relevanz prädiktiver und prognostischer Faktoren. 
Neu im Bereich der systemischen Therapie war, dass erstmals 
über die adjuvante Gabe von Bisphosphonaten diskutiert wurde 
und dass die Therapie mit Trastuzumab bei HER2-Überexpres-
sion jetzt auch für die neoadjuvante Therapie als Standard de-
finiert wurde. Der Stellenwert der Taxane als Bestandteil der 
(neo)adjuvanten Chemotherapie sowie der Aromatasehemmer 
für die endokrine adjuvante Behandlung der postmenopausalen 
Patientin wurden bestätigt. 
Summary
A German working group of 23 breast cancer experts discussed 
the results from the vote at this year’s St. Gallen Consensus 
Conference on Primary Therapy for Early Breast Cancer (March 
11–14, 2009) and came up with some concrete recommenda-
tions for day-to-day therapeutic decisions in Germany. Due the 
fact that the concept of the St. Gallen Consensus Conference 
merely allows for a minimal consensus, the objective of the 
working group was to provide practice-related recommenda-
tions for day-to-day clinical decisions in Germany. One area of 
emphasis at St. Gallen was tumor biology as a starting point 
for reaching individual therapeutic decisions. Intensive discus-
sion was necessary with respect to the clinical relevance of 
predictive and prognostic factors. A new addition to the area 
of systemic therapy was a first-ever discussion of the adjuvant 
administration of bisphosponates and the fact that therapy with 
trastuzumab in HER2 overexpressing breast cancer has been 
defined as the standard for neoadjuvant therapy. The value of 
taxanes as a component of (neo)adjuvant chemotherapy as well 
as the value of aromatase inhibitors for the endocrine adjuvant 
treatment of postmenopausal patients were affirmed. 
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Introduction
This year’s 11th International St. Gallen Consensus Con-
ference on the Diagnosis and Treatment of Primary Breast 
Cancer (March 11–14, 2009) has worldwide significance. This 
year’s panel at St. Gallen was made up of 43 experts from 17 
countries, 3 of whom were representatives from Germany. 
Due to the fact that the recommendations are based on the 
vote of the representatives from different countries with often 
very diverse health systems and resources, it was only possible 
to achieve a minimal consensus. As a result, a German work-
ing group of 23 breast cancer experts discussed the voting re-
sults from St. Gallen as they relate to the therapy situation 
in Germany with the objective of formulating some concrete 
recommendations for day-to-day clinical decision-making in 
Germany.
The objective of this year’s St. Gallen Consensus Confer-
ence was to vote on controversial issues and discuss them 
based on international findings. The results from controlled 
clinical studies form the basis for an evidence-based therapy. 
However, it is always necessary to re-evaluate the significance 
of this ‘evidence’ for therapeutic decision-making in individu-
al cases – while taking the individual circumstances into con-
sideration. 
With this objective in mind, the focus at St. Gallen was on 
10 topic areas. In addition to the classic areas of surgery, ra-
diation, endocrine and cytostatic therapy, other areas includ-
ed the application of targeted substances, as well as the value 
of predictive and prognostic factors. New areas of discussion 
included the adjuvant use of bisphosphonates, fertility pres-
ervation under oncological treatment, as well as male breast 
cancer. The panelists responded to the questions submitted 
for a vote by responding with ‘yes’ (agree), ‘no’ (disagree), or 
‘abstain/don’t know’. 
Prognostic and Predictive Factors
The clinical significance of diverse predictive and prognostic 
factors as markers for certain biological characteristics of tu-
mors was a topic of intensive discussion at St. Gallen. A vote 
was held on the significance of grading, hormone receptor sta-
tus and HER2 status, as well as the clinical value of Ki-67 and 
the use of new molecular tests. 
Grading
Grading was affirmed as a predictive factor for the use of a 
chemotherapy regimen (G3). Discussion also included the 
issue of whether so-called ‘genomic grading’ or other gene 
expression analyses using molecular testing systems provide a 
meaningful supplement to histological grading. While the ma-
jority of the panelists at St. Gallen agreed that in fact they do, 
the German experts currently reject the general clinical use 
of these new testing systems. Their criticism is based on the 
fact that to date only retrospective data are available on the 
value of such analytical methods, access to these data is still 
limited, and these complex procedures have yet to be com-
pletely standardized. 
Estrogen and Progesterone Receptor
The panel participants at St. Gallen voted to quantify the es-
trogen receptor expression based on the percentage of posi-
tive cells. The majority accepted a value of >50% dye-stained 
cells as the cut-off value for a new category of highly endo-
crine-sensitive tumors. The German working group agreed 
that a highly endocrine-sensitive tumor can be assumed at a 
value of >50% positive cells, but that this does not constitute 
an exclusionary criterion. To date there is no known evidence-
based cut-off value for the authoritative definition of an endo-
crine-sensitive or highly sensitive breast carcinoma. Thus the 
German working group pointed out that the described situ-
ation (cut-off >50%) is merely one example of a highly en-
docrine-sensitive tumor and that other constellations do not 
rule out an endocrine sensitivity. Tumors can be less deeply 
dye-stained but still respond to endocrine therapy. 
The majority of the panelists accepted a value of <10% 
positive cells as a cut-off for an endocrine-insensitive tumor. 
Again the German working group disagreed: a tumor is not 
certain to be endocrine-insensitive except in cases where no 
positive cells can be detected. Unlike the other panelists at St. 
Gallen, the German experts urged the use of additional scores 
that take into consideration the intensity of cell staining as 
well as the number of dye-stained cells, in order to quantify 
endocrine sensitivity. It was also asserted that a Remmele 
score ≥9, for example, or an Allred score ≥7 is indicative of 
a tumor with high endocrine sensitivity. The greatest impor-
tance and priority must be placed on adequate quality assur-
ance in determining hormone receptor expression.
The German experts agreed with the St. Gallen panelists 
that the progesterone receptor (PgR) has a prognostic value, 
but does not provide any predictive value for the use of 
tamoxifen or an aromatase inhibitor (AI). The German work-
ing group further asserted that the PgR is merely a general 
predictor for the response to an endocrine therapy. The study 
data on postmenopausal patients show a comparable relative 
risk reduction independent of the PgR expression under  AIs 
as compared to tamoxifen.
HER2 Expression
HER2 overexpression is the precondition for treatment with 
trastuzumab. The discussion involved determining at what im-
munohistochemical (IHC) cut-off value therapy with the mono-
clonal antibody is indicated. The German experts concurred with 
the St. Gallen decision to raise the cut-off value from 10% – as 
defined in the clinical studies – to 30% positive cells (cf. ASCO 
recommendations: Wolfe et al., JCO 2007). This is equivalent to 
IHC3+ (≥30% positive). In cases of doubt, a positive FISH test 
is required in order to initiate treatment with trastuzumab.
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A significant majority of the panelists at St. Gallen con-
sidered HER2 overexpression a predictor for neoadjuvant 
use of anti-HER2 medication. In accord with the German 
experts, St. Gallen recommended the additional use of tras-
tuzumab with HER2 overexpression not only for adjuvant, 
but also for neoadjuvant chemotherapy. In the GBG/AGO 
meta-analysis of neoadjuvant chemotherapy (by Minckwitz 
et al., SABCS 2008, abstract) the additional administration 
of trastuzumab for chemotherapy was an independent predic-
tor for the achievement of a pathological complete remission. 
It was also agreed that HER2 overexpression is a predictor 
for the response to (neo)adjuvant chemotherapy in general. 
Conversely, HER2 overexpression is not a predictor for the 
response to a certain endocrine therapy. However, the higher 
risk associated with HER2 overexpression – similar to a nega-
tive PgR – justifies the primary use of an  AI.
Proliferation Marker Ki-67
The use of the proliferation marker Ki-67 as a prognostic 
and/or predictive factor was discussed intensively at St. Gal-
len. The majority of panelists considered Ki-67 a prognostic 
factor. The vote on the predictive value of Ki-67 was contro-
versial. The German experts currently view Ki-67 as neither 
a valid prognostic nor a predictive factor because there are 
no supporting data available from prospective studies. The 
German working group made reference to unresolved issues 
in the determination of Ki-67, e.g. a lack of standardization, 
the lack of a clearly defined cut-off value, and the fact that Ki-
67 has not been confirmed to be an independent factor in all 
clinical studies. According to the German working group, the 
routine determination of Ki-67 alone currently has no clinical 
relevance for therapeutic decision-making. 
uPA/PAI-1 Determination
The routine determination of uPA/PAI-1 as a prognostic fac-
tor was rejected by the majority of panelists at St. Gallen. The 
German experts did not concur. They view uPA/PAI-1 as a 
valid, standardized, and evidence-based method whose clini-
cal relevance for node-negative breast cancer is supported by 
prospective data. uPA/PAI-1 is a clinically relevant factor for 
the decision for or against adjuvant chemotherapy for tumors 
with a clinically intermediate risk profile. 
Gene Expression Analyses
The clinical significance of molecular gene expression analy-
ses was discussed at St. Gallen based on the example of On-
cotype DX® (Genomic Health, Inc., Redwood City, CA, 
USA) and Mammaprint® (Agendia, Huntington Beach, CA, 
USA). The panel was basically in agreement that the use of 
currently available molecular tests in addition to clinical and 
histopathological parameters, in other words not as the sole 
instrument, can be useful, e.g. in patients with hormone-sensi-
tive breast cancer, for whom it is unclear whether adjuvant 
chemotherapy is indicated, following the consideration of 
histopathological criteria. In cases of doubt, however, these 
patients should be treated within corresponding clinical stud-
ies, such as the MINDACT study. The German experts cur-
rently see no value in molecular tools, such as gene expression 
analyses, outside of clinical studies. Their main argument is 
that only retrospective data are available to date. 
CYP2D6 Determination
As posited at St. Gallen, the German working group also does 
not currently view CYP2D6 as a general predictor for endo-
crine therapy decision-making in postmenopausal patients 
and for the question of whether they should be treated with 
tamoxifen or an  AI. As a result, they – as well as the majority 
of the panelists at St. Gallen – reject a routine CYP2D6 test in 
patients who are supposed to receive tamoxifen. The German 
experts pointed out that currently there are no prospective 
data available to justify a general CYP2D6 test. The percent-
age of patients who metabolize tamoxifen very poorly (‘poor 
metabolizers’) is only about 6–7% in Germany. The clinical 
consequences are unclear for the nearly 20% of ‘intermediate 
metabolizers’. If a valid CYP2D6 test is already available from 
a standardized laboratory, then the patient should be notified 
about the findings and receive the necessary advice. However, 
an active recommendation for a CYP2D6 test is currently not 
indicated.
Local Breast Cancer Therapy
Axillary Dissection, Additional Resection
At St. Gallen the votes on local therapy for primary early 
breast cancer focused on axillary dissection, additional resec-
tion, and radiation therapy. In each case, a significant major-
ity of the St. Gallen panel considered the sentinel lymph node 
biopsy (SLNB) the standard in cases of invasive breast cancer 
with clinically normal axilla (cN0) – with the exception of in-
flammatory breast cancer (T4d). Axillary dissection should be 
performed in cases where micrometastases are detected in the 
sentinel SLNB. Where necessary, axillary dissection may be 
dispensed with only in select patients with low risk (T ≤ 1 cm, 
N0, G1, max. 1 affected SLN out of at least 5 removed SLN, 
L0, V0 ER/PgR-positive, HER2-negative). 
Likewise, considerable majorities at St. Gallen were in 
favor of additional resection. It was affirmed that additional 
resection is necessary in cases of an invasive carcinoma or 
DCIS (ductal carcinoma in situ) with positive margins (R1). 
Conversely, the majority agreed that additional resection is 
not necessary in cases of an accompanying LCIS (lobular car-
cinoma in situ). The German experts concurred with the vote 
for the accompanying LCIS, but they pointed out that the 
situation is totally different in cases of a solitary, dedifferenti-
ated (plenomorphic) LCIS. Discussions are currently ongoing 
to reclassify LCIS and to differentiate the types more clearly 
– with corresponding surgical implications. 
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Similarly controversial at St. Gallen was the issue discussed 
by the German experts as to whether a resection margin of 
2 mm is sufficient to forego an additional resection with the 
presence of a solitary DCIS. This question was put to a vote 
and verbally approved at St. Gallen. The discussion was based 
on the data from a current meta-analysis with a total of over 
4,000 patients, according to which a 2-mm resection margin is 
sufficient in cases of DCIS (Dunne et al., JCO 2009). 
This question and vote were in clear opposition to the 
2009 recommendations of the ‘AGO Kommission Mamma’ 
and the S3 guideline of the German Cancer Society, which 
recommend a resection margin ≥5–10 mm in cases of solitary 
DCIS. The current data from the meta-analysis could result 
in an important change in strategy. The majority of German 
experts was of the opinion that, depending on the size of the 
tumor, free resection margins with a minimum distance of >2 
mm are necessary in the case of a solitary DCIS (exceptions: 
skin, pectoral fascia). However, the German working group 
also pointed out that these changes still need to be discussed 
before the German guidelines can be modified. 
Radiation Therapy
A significant majority of the panelists at St. Gallen affirmed 
radiation therapy as the post-operative standard for patients 
with DCIS. About two-thirds of the panelists voted in ap-
proval of foregoing radiation in cases of older patients (>75 
years of age) and those with low-grade DCIS (low risk). The 
German working group voted in favor in both votes. They did 
present one condition: an individual risk/benefit analysis must 
be performed prior to foregoing radiation therapy in older 
women and/or in low-risk situations. 
The majority of panelists approved accelerated whole 
breast radiation therapy (WBRT) as the acceptable option 
for patients over 60 years of age with invasive cancer. The 
German working group concurred. Conversely, the vote on 
the value of intraoperative partial breast radiation therapy 
(PBRT) was intensively debated. The majority of the panelists 
at St. Gallen classified PBRT as an experimental procedure. 
The German working group concurred with the majority de-
cision. A minority of German experts pointed out, however, 
that PBRT represents an option for certain day-to-day clinical 
situations, within the framework of clinical studies wherever 
possible, e.g. for low-risk patients (T1, N0, L0, V0, G1, ER/
PgR-positive, unicentric, postmenopausal, HER2-negative, no 
EICs). Essentially the German working group referred to the 
ASCO and ASTRO recommendations, which clearly define 
when PBRT can be indicated, e.g. instead of boost radiation, 
and when it is contraindicated. 
There was consensus on the St. Gallen vote concerning the 
indication for radiation therapy in breast cancer patients fol-
lowing mastectomy. It is the standard for patients with at least 
four affected lymph nodes and an option for patients with 1–3 
affected lymph nodes – especially for younger women (<50 
years of age) and those with unfavorable prognostic factors. 
The EBCTCG (Early Breast Cancer Trialist Collaborative 
Group) meta-analysis found a survival benefit for patients 
with 1–3 affected lymph nodes after 15 years (Peto et al., 
NEJM 2005). According to a subgroup analysis, the survival 
benefit applied especially to patients with 2–3 affected lymph 
nodes. The German group of experts criticized the fact that 
the systemic therapy included in the Peto analysis typically 
did not conform to today’s standards.
For years follow-up radiation has been the standard follow-
ing breast-conserving operations. According to the vote at St. 
Gallen, this is also valid for patients with minor, hormone-sen-
sitive breast cancer (T1N0), who receive endocrine treatment, 
as well as for postmenopausal patients with hormone-sensitive 
breast cancer and a life expectancy of more than 10 years. The 
German experts concurred with the St. Gallen vote. They also 
pointed out that the local recurrence rate in older patients 
was considerably reduced through the use of radiation as well 
(1 vs. 7% after 10 years). The German working group empha-
sized that endocrine therapy cannot replace radiation therapy 
following breast-conserving operations even for older patients 
(>70 years of age, ER-positive), following an unclear vote on 
the issue at St. Gallen (51 vs. 46%).
Endocrine Therapy
Premenopausal Patients
For premenopausal patients with hormone-sensitive primary 
breast cancer both the exclusive treatment with tamoxifen 
(preferred), as well as the combination of tamoxifen plus 
ovarian function suppression (OFS), is one possible standard. 
The German working group concurred with the majority of 
the panelists at St. Gallen on both of these options. However, 
the German experts were of the more restricted opinion that 
the combination treatment with tamoxifen plus OFS (LHRH 
analog) is only an additional option in individual cases, e.g. for 
patients under 40 years of age. Since premenopausal patients 
with increased risk of recurrence usually receive chemothera-
py in addition to endocrine treatment, the scope of application 
for LHRH analogs plus tamoxifen is relatively narrow. The 
German working group warned of overtreatment with LHRH 
analogs. Treatment with OFS plus tamoxifen can reduce the 
risk of recurrence in women under 40 years of age and with 
reinstated ovarian function following chemotherapy. Whether 
and/or which patients actually benefit from the additional ad-
ministration of the LHRH analog is currently being investi-
gated by the SOFT and the TEXT studies, among others.
From the German standpoint, OFS alone in otherwise 
healthy women is the standard. At least 40% of the panelists 
at St. Gallen viewed OFS alone as a standard approach. The 
German working group pointed out that OFS alone only rep-
resents a therapy option in individual cases, e.g. in women 
with a medical contraindication to tamoxifen. With respect 
to the duration of therapy, the German working group added 
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that tamoxifen can be used for 5 years and LHRH analogs can 
be used for 2–5 years, depending on the therapeutic concept. 
Due to time limitations, the St. Gallen conference did not vote 
on the use of  AIs in premenopausal patients with hormone-
sensitive breast cancer. Here the German working group 
added that  AIs alone are not typically indicated in premeno-
pausal patients. They are only an option in cases of medical 
contraindications to tamoxifen – and then only in combina-
tion with LHRH analogs.
Postmenopausal Patients
The discussion focused on the value of tamoxifen versus  AIs 
in the treatment of postmenopausal patients with hormone-
sensitive breast cancer. Over the course of the voting, the 
majority of St. Gallen panelists considered exclusive treat-
ment with tamoxifen as well as treatment with an AI possi-
ble standard approaches for postmenopausal patients. Here 
the German working group specified that from the German 
standpoint, exclusive treatment with tamoxifen is only an op-
tion for postmenopausal patients with hormone receptor posi-
tive breast cancer and very low risk of recurrence or advanced 
age. Moreover, tamoxifen is the standard for the prevention 
of contralateral breast cancer. In all other cases AI is a sturdy 
component of adjuvant endocrine therapy for postmenopau-
sal patients with hormone-sensitive breast cancer.
From the German standpoint, if there is an indication for 
AI, then it should initially be used in accordance with the indi-
vidual risk profile of the patient or after treatment for 2 years 
with tamoxifen. The greater the recurrence risk is (stage, es-
pecially nodal status, tumor size, HER2 status, PgR status, 
proliferation index), the greater the preference for the initial 
use of AI from the German standpoint. If the AI has been 
used up front, then there is the option to switch to tamoxifen 
after 2 years, e.g. in patients with AI-related adverse reac-
tions. As a result, the duration of AI therapy will vary and 
usually lasts 2–5 years, depending on the therapeutic concept. 
For an indication for treatment with an AI, the panelists at St. 
Gallen had a preference for beginning a therapy with an AI, 
which included both the 5-year up front therapy, as well as 
the switch to tamoxifen after 2 years (inverse sequence). Only 
15% of the panelists voted for the planned staggered use of 
the AI after 2–3 years of therapy with tamoxifen.
HER2 Overexpression with Hormone-Sensitive Breast Cancer
The majority opinion among the panelists at St. Gallen was 
that a HER2 overexpression with hormone-sensitive breast 
cancer does not represent a preferred indication for an  AI. 
The German working group found it important to point out 
that the HER2 status is merely a predictor for the response 
to trastuzumab, but not a predictive factor for the use of AI 
versus tamoxifen. Patients with hormone-sensitive HER2-
overexpressing breast cancer usually respond more poorly to 
an endocrine therapy than patients without HER2 overex-
pression. This is equally true for both tamoxifen and AI. The 
relatively better effect of the AIs as compared to tamoxifen 
depends on the HER2-expression; the absolute benefit alone 
is greater for the AI in cases with HER2 overexpression. Thus 
the German working group agreed that treatment with an AI 
is recommended due to the increased risk of recurrence as-
sociated with HER2 overexpression in postmenopausal pa-
tients. 
Endocrine adverse reactions under adjuvant endocrine 
therapy are not an indication of an especially good therapeu-
tic response in patients. The German experts agreed here with 
the vote at St. Gallen without reservations. They were also in 
agreement with the vote at St. Gallen concerning the ques-
tion of the options for conserving ovarian function in patients 
during chemotherapy. To date a standard method has yet to 
be defined in this regard. At present, ovarian stimulation and 
IVF (in vitro fertilization) are the only established methods 
for effective cryopreservation. 
Male Breast Cancer
In rare cases men can also develop breast cancer (approxi-
mately 400–500 new cases per year in Germany). The endo-
crine therapy standard here is treatment with tamoxifen. AI is 
currently not indicated for men. The German working group 
added that data collection on male breast cancer should be 
more centralized and greater effort should be made to con-
duct clinical studies on the disease.
Adjuvant Chemotherapy
Hormone-Sensitive Breast Cancer without HER2  
Overexpression
The focus here was on the use of adjuvant chemotherapy in 
patients with highly endocrine-sensitive breast cancer. A ma-
jority on the St. Gallen panel answered ‘yes’ to the question 
of whether a highly endocrine-sensitive tumor with HER2 
overexpression responds less well to adjuvant chemotherapy. 
The additional administration of adjuvant chemotherapy was 
thus considered to be ‘less useful’ for clinical use in hormone 
receptor positive patients without HER2 overexpression. The 
German working group interpreted these questions different-
ly than the consensus panel. Both the Oxford meta-analysis 
(EBCTCG, Lancet 2005) as well as a current meta-analysis 
with docetaxel-containing regimens (by Andre et al., JCO 
2008) demonstrate that patients with a chemotherapy indica-
tion – regardless of age and hormone receptor status – ben-
efited from an adjuvant chemotherapy with a similar, relative 
risk reduction. This just means that patients with low risk of 
recurrence have a slighter absolute benefit from the adjuvant 
chemotherapy.
Based on the regimen used, controlled clinical studies on 
paclitaxel administered for 3 weeks showed that the effect was 
somewhat slighter in patients with hormone receptor posi-
tive breast cancer than in hormone receptor negative women 
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(Hayes et al., NEJM 2007). However, this might be related 
with an underdosing of the substance. The three-week ad-
ministration of docetaxel and/or the weekly administration of 
paclitaxel are similarly effective. In the BCIRG 001 study pa-
tients with hormone receptor positive breast cancer benefited 
just as much from the treatment with the triple TDocAC com-
bination as the hormone receptor negative patients (Martin et 
al., NEJM 2005). 
Standard Regimen Depending on HER2 Status
The majority of the St. Gallen panel rejected the notion that 
there are different standard chemotherapy regimens for pa-
tients with early breast cancer depending on the HER2 and/or 
hormone receptor status of the tumor. This was also the case 
for ‘triple negative’ breast cancers (ER–, PgR–, HER2–). The 
German working group concurred with this opinion. 
Anthracycline- and taxane-containing regimens are the 
standard for the adjuvant treatment of patients with HER2-
positive and HER2-negative breast cancer. For each type 
there are several regimens to choose from – depending on 
nodal status and/or the individual risk constellation. Patients 
with HER2 overexpression require trastuzumab in addition to 
chemotherapy. Trastuzumab can be used sequentially or si-
multaneously with the chemotherapy. 
Both of the anthracycline-containing, triple combination 
FEC and/or FAC regimens, 6 cycles each, are the standard 
for patients without lymph node involvement (N0) and an 
indication for chemotherapy. In direct and indirect compari-
sons the triple combinations are superior to the CMF regi-
men (EBCTCG, Lancet 2005). This could not be proven for 
the anthracycline-containing double combinations even with 
more than four therapy cycles. In cases of increased risk of 
recurrence (G ≥ 2, T > 2 cm, age < 35 years, HR-negative, 
according to GEICAM 9805) the German working group rec-
ommends the use of 6 cycles of TDocAC (docetaxel, doxoru-
bicin, cyclophosphamide) (table 1). The TDocAC regimen in 
the randomized phase III study achieved a significant advan-
tage in disease-free survival time for patients without lymph 
node involvement compared with 6 cycles of FAC (Martin et 
al., ASCO 2008, abstract).
For patients with lymph node involvement, the German 
working group recommends, as in the AGO guidelines, pri-
marily the following anthracycline-/taxane-containing regi-
mens: 6 × TDocAC, 3 × FEC-3 × Doc, 4 × AC-12 × Pac/q1W, 4 
× AC-4 × Doc, as well as 4 × EC-4 × Doc (table 1). 
The Role of Dose-Dense Chemotherapy
Adjuvant treatment with dose-dense chemotherapy was also 
considered an option at St. Gallen. The German experts con-
curred with this opinion, adding: dose-dense chemotherapy is 
an option for risk patients with extensive lymph node involve-
ment at experienced centers. Established regimens include 
the ETC regimen (epirubicin, paclitaxel, cyclophosphamide) 
as well as dose-dense administration of AC-paclitaxel, every 
two weeks. In both regimens the patients also require G-CSF 
support (Moebus et al., SABCS 2006, abstract; Citron et al., 
JCO 2003).
Value of Anthracyclines in the Adjuvant Situation
If there are contraindications against anthracyclines, e.g. due 
to a preexisting cardiac disease or risk constellation, the TDoc-
CbH regimen (docetaxel, carboplatin, trastuzumab) may be an 
alternative for cases of HER2 overexpression – assuming that 
there is no resulting contraindication for trastuzumab. The 
BCIRG 006 study demonstrated the efficacy of TDocCbH as an 
anthracycline-free, trastuzumab-containing regimen (Slamon 
et al., SABCS 2006, abstract). However, it should be noted 
that only patients without cardiac impairment were enrolled 
in that study.
The double combination TDocC (4 cycles of docetaxel/cy-
clophosphamide) was discussed as the standard option for pa-
tients without HER2 overexpression and anthracycline con-
traindication. There was no majority agreement on this at St. 
Gallen. The German working group considers the 4 cycles of 
AC (doxorubicin, cyclophosphamide) in the direct phase III 
study comparison (Jones et al., JCO 2009). The TDocC com-
bination with 6 cycles is currently being further validated in 
clinical studies due to the fact that the therapy duration of 4 
cycles (12 weeks), which has been studied in clinical studies, 
appears to be too short in neoadjuvant therapy, according to 
the meta-analysis (Minckwitz et al., SABCS 2008, abstract). 
Moreover, TC has not yet been compared with any of the cur-
rent standard combinations with three substances. 
Regimen for node-positive situations Regimen for node-negative situations
6 × TDocAC standard
3 × FEC – 3 × docetaxel 6 × FEC, 6 × FAC
4 × AC/EC – 4x docetaxel with high risk of recurrence a
4 × AC – paclitaxel 12 × q1W. 6 × TDocAC
Dose-dense regimen
ddAC – paclitaxel q2W. + G-CSF ETPacC + G-CSF
aG≥2, T>2cm, age <35 years, HR-negative – GEICAM 98 05 
Table 1. Adjuvant 
chemotherapy 
– standard regimen 
according to Zurich 
Consensus 2009  
(no standard regimen 
was designated at  
St. Gallen)
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Study Participation Encouraged
Participation in randomized clinical studies was essentially en-
couraged. Different adjuvant therapy optimization studies are 
currently being conducted in Germany: the use of the anthra-
cycline-free 6 × TDocC regimen (docetaxel/cyclophosphamide) 
in patients without HER2 overexpression is being compared 
with EC-docetaxel in the Plan B study and with FEC-docetax-
el in the SUCCESS C study. The dose-dense/tailored concept 
is being further validated in the PANTHER study in patients 
with lymph node involvement with tolerability-related ad-
justed doses of EC-Doc versus FEC-Doc. The use of TDocCbH 
is being studied in patients with HER2-overexpressing breast 
cancer plus/minus bevacizumab.
Neoadjuvant Chemotherapy
The neoadjuvant therapeutic concept has become well estab-
lished in the treatment of early breast cancer. This was clearly 
expressed at St. Gallen. The German experts also pointed out 
that an especially high value is placed on neoadjuvant therapy 
in Germany. The therapeutic approach was further developed 
and validated in Germany within the framework of large pro-
spective clinical studies. The structure of the healthcare sys-
tem in Germany makes it easier to use this form of therapy 
because overall patient care is primarily in the hands of the 
gynecologist.
Indication for Neoadjuvant Therapy
Neoadjuvant chemotherapy basically comes into question if 
adjuvant chemotherapy is also indicated. The same regimens 
for adjuvant therapies can be used in neoadjuvant therapies 
as well. This was affirmed by the great majority of the pan-
elists at St. Gallen (97%). According to the German experts, 
the main objectives of neoadjuvant therapy are to increase the 
rate of breast-conserving operations (BCT) and to improve 
operative options. They emphasized that not only does neo-
adjuvant therapy enable operability per se, but it also makes 
the breast-conserving operation easier to perform because 
less tissue has to be removed when the response is good (‘new 
limits’). It is beyond dispute that the operation following neo-
adjuvant chemotherapy requires an experienced surgeon.
Another benefit of neoadjuvant therapy is in vivo chemo-
sensitivity testing. It enables the early individual detection of 
a therapeutic response, thereby also making it easier to de-
fine new predictive factors. The achievement of a pathologi-
cal complete remission (pCR) is a valid surrogate marker for 
long-term survival. 
Similar to the situation with adjuvant therapy, neoadju-
vant chemotherapy is less effective in patients with a low risk 
profile, e.g. a tumor with a low proliferation rate. This was 
affirmed by 59% of the panelists at St. Gallen. A low prolif-
eration rate is to be assumed, for example, in cases of a highly 
differentiated tumor, a clearly hormone-sensitive breast car-
cinoma, a low Ki-67 value, and an invasive lobular tumor as 
well, with some reservations. 76% of the St. Gallen panelists 
rejected the use of a neoadjuvant therapy in these patients. 
The German working group pointed out that in this situation 
even adjuvant chemotherapy is only presumably indicated 
and it is difficult to define a low-proliferating tumor; thus it is 
necessary to consider whether or not a neoadjuvant therapy is 
useful in each individual case. 
Substance Selection for Neoadjuvant Chemotherapy
The German experts concurred with the clear majority of the 
panelists at St. Gallen concerning the substance selection for 
neoadjuvant chemotherapy. Anthracycline- and taxane-con-
taining regimens are the standard. With HER2 overexpres-
sion an anti-HER2 medication with trastuzumab is indicated 
in addition to neoadjuvant chemotherapy. This was affirmed 
by 90% of the panelists at St. Gallen. 
At St. Gallen there was no vote on the duration of therapy 
for neoadjuvant chemotherapy. Based on the large meta-
analysis of GBG/AGO (by Minckwitz et al., SABCS 2008, ab-
stract) the German working group recommended a treatment 
duration of at least 18 weeks. The German working group 
pointed out that an additional postoperative chemotherapy 
regimen following previous neoadjuvant chemotherapy out-
side of clinical studies is not indicated and the operation fol-
lowing neoadjuvant chemotherapy should be performed 
within the new tumor margins. Moreover, a breast-conserv-
ing operation following neoadjuvant chemotherapy is not 
indicated in cases of extensive microcalcification, inoperable 
breast cancer and/or a T4 tumor with no therapeutic response, 
as well as in all cases when post-operative radiation following 
a breast-conserving operation is not possible.
Neoadjuvant Endocrine Therapy
Neoadjuvant endocrine therapy is essentially an option in 
cases of highly hormone-sensitive tumors. 90% of the pan-
elists at St. Gallen agreed; the German experts concurred. 
The duration of therapy still remains unclear. This was also 
evident in the voting results: 20% voted for 1–4 months, 43% 
for 4–8 months and 37% until the best therapeutic response 
is achieved. The German working group, in accord with the 
voting results at St. Gallen, favored a duration of therapy of at 
least 4–8 months.
Bisphosphonates, Targeted Substances, Lifestyle
Adjuvant Use of Bisphosphonates
At St. Gallen a vote was held for the first time on the use of 
bisphosphonates in early primary breast cancer. However, the 
question put to a vote concerning adjuvant use in addition to 
endocrine therapy focused on the bisphosphonate zoledronate 
(every 6 months, i.v.). The panelists at St. Gallen rejected the 
general adjuvant use of zoledronate in addition to adjuvant 
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endocrine therapy regardless of the menopausal status of the 
patient. 
The German working group made additional remarks here 
by adding that patients can benefit from the use of a bisphos-
phonate (zoledronate, clodronate) as a component of an ad-
juvant tumor therapy regardless of menopausal status and the 
remaining adjuvant therapy. Current clinical findings have 
shown that additional adjuvant treatment with a bisphospho-
nate reduces the rate of recurrence, which also showed up as 
a lower mortality rate in individual studies. Serious adverse 
reactions or complications were rare in the adjuvant therapy 
studies.
The German working group also pointed out that bisphos-
phonates can reduce the risk of tumor therapy-induced osteo-
penia and/or osteoporosis (TTIO) and the risk of fracture in 
patients with manifest osteoporosis. As a result, the German 
experts see an indication for biphosphonates not only for the 
treatment but also for the prevention of TTIO, following an 
adequate assessment of the risks – despite the lack of an au-
thorization for such an indication. 
Targeted Therapy
The St. Gallen panel affirmed that patients with HER2 over-
expressing early breast cancer should receive trastuzumab in 
addition to (neo)adjuvant chemotherapy. The German ex-
perts concurred with this opinion without reservations. A dif-
ferentiation of the chemotherapy is not recommended. The 
panelists at St. Gallen, as well as the German experts, are in 
agreement that trastuzumab is only indicated together with 
an indication for chemotherapy. The panelists at St. Gallen 
viewed the simultaneous and sequential administration of 
trastuzumab as equally effective options. The majority of the 
German experts concurred with this opinion. 
However, a minority of the German experts favored the 
simultaneous administration of trastuzumab for chemother-
apy, while pointing out inter alia that the clinical findings 
here show slight benefits. This is comprehensible insofar as 
the preclinically observed synergistic effects between chemo-
therapy and trastuzumab can best be put to use with simulta-
neous administration. It should be noted that there is a higher 
cardiac risk associated with the simultaneous administration 
of trastuzumab and anthracyclines, which can be avoided by 
using TDocCbH. 
The majority among the German working group concurred 
that currently there is not enough evidence in support of si-
multaneous or sequential administration of trastuzumab plus 
chemotherapy. The therapeutic decision should be made on 
an individual basis – also in relation to the chemotherapy used 
or the planned studies. It is vital that patients with HER2-
overexpressing breast cancer receive trastuzumab in addition 
to chemotherapy. The duration of the trastuzumab therapy is 
one year. Currently there is no indication for the adjuvant use 
of other targeted therapies outside of clinical studies. This is 
also true for bevacizumab. The St. Gallen panel and the Ger-
man experts concurred that bevacizumab is currently not in-
dicated in adjuvant therapy situations. Participation in clinical 
studies, e.g. the BETH study, is recommended.
Lifestyle and Complementary Medicine
Issues of patient lifestyle and its possible effects on thera-
peutic success, as well as the role of complementary medi-
cine, were not discussed at St. Gallen. The German working 
group added its own observation that lifestyle, especially the 
combination of physical activity and well-balanced, healthy 
nutrition can have a positive influence on the prognosis for 
patients with breast cancer. This is especially applicable to the 
adjuvant therapy situation. The influence of lifestyle on the 
prognosis is currently being studied prospectively in the SUC-
CESS C study. The German working group urged that special 
care should be taken with complementary and especially so-
called alternative medications, as well as extreme diets, which 
can have a negative effect on the chances for recovery. 
Erratum
In the article ‘Zurich Consensus: German Expert Opinion on the St. Gallen Votes 
on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of 
Early Breast Cancer)’, Breast Care 2009;4:109-116 (DOI:10.1159/000212164), the 
following passage was missing:
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